Drug – bio-affecting and body treating compositions – Preparations characterized by special physical form – Capsules
Reexamination Certificate
2006-04-25
2009-12-15
Carr, Deborah D (Department: 1621)
Drug, bio-affecting and body treating compositions
Preparations characterized by special physical form
Capsules
C514S534000, C554S063000
Reexamination Certificate
active
07632519
ABSTRACT:
Described here are TRPV1 agonist compounds and their methods of synthesis and use. In addition to specifically identified compounds, capsaicin prodrugs, gemini dimers, and mutual prodrugs are also described. Formulations of the TRPV1 agonist compounds may be in the form of a liquid, tablets, capsules, gel, cream, emulsion, a patch, or the like. Methods for treating medical conditions using the compounds, compositions, or prodrugs described, are also provided.
REFERENCES:
patent: 4493848 (1985-01-01), LaHann et al.
patent: 4544669 (1985-10-01), LaHann et al.
patent: 5094782 (1992-03-01), Chen et al.
patent: 2003/0064122 (2003-04-01), Goldberg et al.
patent: 2004/0122089 (2004-06-01), Martin et al.
patent: 2006/0034872 (2006-02-01), Woolf
patent: 0 132 115 (1985-01-01), None
patent: 0 132 115 (1985-01-01), None
patent: 0 132 346 (1985-01-01), None
patent: 0 132 346 (1985-01-01), None
patent: 0 149 544 (1985-07-01), None
patent: 0 149 544 (1985-07-01), None
patent: 0 149 544 (1985-07-01), None
patent: 1 437 344 (2004-07-01), None
patent: 1437344 (2004-07-01), None
patent: 2 168 976 (1986-07-01), None
patent: 2168976 (1986-07-01), None
patent: 10-114649 (1998-05-01), None
patent: 10114649 (1998-05-01), None
patent: 10120558 (1998-05-01), None
patent: 2003-055314 (2003-02-01), None
patent: WO-03/102156 (2003-12-01), None
patent: WO-03/102156 (2003-12-01), None
patent: WO-03/102156 (2003-12-01), None
patent: WO03102156 (2003-12-01), None
Hammell, D.C. et al. (Jun. 18, 2004). “A Duplex “Gemini” Prodrug of Naltrexone for Transdermal Delivery,” J. Control Release 97(2):283-290.
Otagiri, M. et al. (1999). “Improving the Pharmacokinetic and Pharmacodynamic Properties of a Drug by Chemical Conversion to a Chimera Drug,” J. Control Release 62(1-2):223-229.
Sloan, K.B. ed. (1992). Prodruqs: Topical and Ocular Druq Delivery, Marcel Dekker, Inc.:NY, NY, vol. 53, pp. vii-viii (Table of Contents Only.).
Anand, P. (Sep. 2003). “Capsaicin and Menthol in the Treatment of Itch and Pain: Recently Cloned Receptors Provide the Key,”Gut52(9):1233-1235.
Bley, K.R. (2004). “Recent Developments in Transient Receptor Potential Vanilloid Receptor 1 Agonist-Based Therapies,”Expert Opin. lnvestig. Drugs13(11):1445-1456.
Carlton, S.M. et al. (May 1998). “Attenuation of Formalin-Induced Nociceptive Behaviors Following Local Peripheral Injection of Gabapentin,”Pain76(1-2):201-207.
Caterina, M.J. et al. (2001). “The Vanilloid Receptor: A Molecular Gateway to the Pain Pathway,”Annu. Rev. Neurosci.24:487-517.
Debreceni, A. et al. (1999). “Capsaicin Increases Gastric Emptying Rate in Healthy Human Subjects Measured by13C-Labeled Octanoic Acid Breath Test,”J. Physiol.(Paris) 93(5):455- 460.
Del Rosso, J.Q. (Mar. 2006). “Combination Topical Therapy for the Treatment of Psoriasis,”Journal of Drugs in Dermatology5(3):232-234.
Ellis, C.N. et al. (Sep. 1993). “A Double-Blind Evaluation of Topical Capsaicin in Pruritic Psoriasis,”J. Am. Acad. Dermatol.29(3):438-442.
Fukuhara, A. (1996). “Stereoselective Disposition of Flurbiprofen From a Mutual Prodrug with a Histamine H2-Antagonist to Reduce Gastrointestinal Lesions in the Rat,”Chirality8(7):494-502.
Gonzalez, R. et al. (Jun. 1998). “Effect of Capsaicin-Containing Red Pepper Sauce Suspension on Upper Gastrointestinal Motility in Healthy Volunteers,”Dig. Dis. Sci.43(6):1165-1171.
Hammell, D.C. et al. (Jun. 18, 2004). “A Duplex “Gemini” Prodrug of Naltrexone for Transdermal Delivery,”J. Control Release97(2):283-290.
Hughes, S.R. et al. (Sep. 4, 1992). “Olvanil: More Potent than Capsaicin at Stimulating the Efferent Function of Sensory Nerves,”Eur. J. Pharmacol.219(3):481-484.
Jordt, S-E. et al. (Aug. 2003). “Lessons from Peppers and Peppermint: The Molecular Logic of Thermosensation,”Curr. Opin. Neurobiol.13(4):487-492.
Nelson, A.G. et al. (2000). “The Effect of Capsaicin on the Thermal and Metabolic Responses of Men Exposed to 38°C. for 120 Minutes,”Wilderness Environ. Med.11(3):152-156.
Otagiri, M. et al. (1999). “Improving the Pharmacokinetic and Pharmacodynamic Properties of a Drug by Chemical Conversion to a Chimera Drug,”J. Control Release62(1-2):223-229.
Sathyanarayana, M.N. (2006). “Capsaicin and Gastric Ulcers,”Crit. Rev. Food Sci. Nutr.46(4):275-328.
Sloan, K.B. ed. (1992).Prodrugs: Topical and Ocular Drug Delivery, Marcel Dekker, Inc.:NY, NY, vol. 53, pp. vii-viii (Table of Contents Only.).
Walpole, C.S.J. et al. (Jul. 19, 1996). “Similarities and Differences in the Structure-Activity Relationships of Capsaicin and Resiniferatoxin Analogues,”J. Med. Chem.39(15):2939-2952.
Baldessari A. et al. (1987). “C NMR Spectral Data of SomeN-Vanillyl-,N-Piperonyl- andN-Veratryl-Alkylaminoalkylamides,”Magn. Res. Chem.25:1012-1018.
Bennett, D.J. et al. (1968). “Constitution and Biosynthesis of Capsaicin,”J. Chem. Soc. C.1:442-446.
Brand, L. et al. (1987). “NE-19550: A Novel, Orally Active Anti-Inflammatory Analgesic,”Drugs Under Experimental and Clinical Research13(5):259-265.
Carr, J.L. et al. (Jan. 1, 2006). “In vitro Photo-Release of a TRPV1 Agonist,”Bioorganic&Medicinal Chemistry Letters16(1):208-212.
Chen, I.J. et al. (Apr.-May 1992). “Hypotensive and Antinociceptive Effects of Ether-Linked and Relatively Non-Pungent Analogues ofN-nonanoyl Vanillylamide,”European Journal of Medicinal Chemistry27(3):187-192.
Couch, M.W. et al. (1972). “Mass Spectrometry of Benzylamines and Benzylamine Derivatives,”Org. Mass. Spectrometry6:21-32.
Couch, M.W. et al. (Jan.-Mar. 1972). “N-Ethyl-N-(Trimethylsilyl)Benzylamine,”Arch. Mass. Spectral Data3(1):32-33.
Furuya, I. et al. (2003).“Preparation of Nonvolatile Stable Odorless Nonirritating Esters of Hydroxycinnamic Acid Derivatives and Their Use as Antioxidants,”CAPLUS2003:143380, two pages.
International Search Report mailed Oct. 26, 2006, for PCT Application No. PCT/US2006/015785, filed Apr. 25, 2006, nine pages.
Jones, E.C.S. et al. (1925). “The Relation Between Chemical Constitution and Pungency in Acid Amides,”J. Chem. Soc.127(II):2588-2598.
Kosuga, M. et al. (1998). “Agents Enhancing Bioactivity of Shineki (Meaning Water in Chinese Medicine) Containing Benzene Derivatives and Their Compositions,”CAPLUS1998:274844, two pages.
Micko (1899).Chem Zentralbl.70(I):293-294.
Substance Identification: Beilstein Registry No. 2943902,Beilstein Institut zur Foerderung der Chemischen Wissenschaften, two pages, 1987.
Substance Identification: Beilstein Registry No. 3111367,Beilstein Institut zur Foerderung der Chemischen Wissenschaften, one page, 1968.
Substance Identification: Beilstein Registry No. 3112056,Beilstein Institut zur Foerderung der Chemischen Wissenschaften, two pages, 1968.
Substance Identification: Beilstein Registry No. 3455977,Beilstein Institut zur Foerderung der Chemischen Wissenschaften, two pages, 1925.
Substance Identification: Beilstein Registry No. 3491177,Beilstein Institut zur Foerderung der Chemischen Wissenschaften, two pages, 1899.
Wu, P.C. et al. (Feb. 1997). “Development and Evaluation of Transdermal Patches of Nonivamide and Sodium Nonivamide Acetate,”Die Pharmazie52(2):135-138.
Zhao, J. et al. (Apr. 18, 2006). “Caged Vanilloid Ligands for Activation of TRPV1 Receptors by 1- and 2-Photon Excitation,”Biochemistry45(15):4915-4926.
Bley Keith R.
Jamieson Gene Curtis
Muhammad Naweed
Carr Deborah D
Morrison & Forester LLP
NeurogesX, Inc.
LandOfFree
TRPV1 agonist compounds, formulations, prodrugs, methods for... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with TRPV1 agonist compounds, formulations, prodrugs, methods for..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and TRPV1 agonist compounds, formulations, prodrugs, methods for... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4124942